INCY · Insider Trading
Incyte Genomics Inc
Every open-market purchase and sale reported by INCY officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Form 4 Filings
50
most recent
Open-Market Buys
0
code P
Sales
6
code S
Reporting Insiders
25
current holders
INCY — Recent Form 4 Transactions (latest 2026-10-19)
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-19 | Pablo J Cagnoni | President, Global Head of R&D | MIXED | — | −$124.04K |
| 2026-10-05 | Lee Heeson | EVP, Head of Incyte Intl | F | −463 | −$54.24K |
| 2026-10-02 | Paul J Clancy | Director | A | +203 | +$24.63K |
| 2026-10-02 | Edmund Harrigan | Director | A | +206 | +$25.00K |
| 2026-10-02 | Baker Bros. Advisors (GP) LLC | Director | A | +3,864 | — |
| 2026-09-24 | David H Gardner | EVP, Chief Strategy Officer | F | −920 | −$116.78K |
| 2026-09-17 | Pablo J Cagnoni | President, Global Head of R&D | MIXED | — | −$1.26M |
| 2026-08-27 | Ramitpal K Basi | EVP, Human Resources | F | −504 | −$65.38K |
| 2026-08-20 | Pablo J Cagnoni | President, Global Head of R&D | Sell | −10,801 | −$1.36M |
| 2026-08-14 | Pablo J Cagnoni | President, Global Head of R&D | Sell | −10,803 | −$1.30M |
| 2026-08-07 | Pablo J Cagnoni | President, Global Head of R&D | Sell | −10,640 | −$1.31M |
| 2026-08-07 | Patrick A Mayes | EVP & Chief Scientific Officer | MIXED | — | −$38.67K |
| 2026-08-07 | Patrick A Mayes | EVP & Chief Scientific Officer | MIXED | — | −$38.67K |
| 2026-08-07 | Pablo J Cagnoni | President, Global Head of R&D | Sell | −10,640 | −$1.31M |
| 2026-08-04 | Pablo J Cagnoni | President, Global Head of R&D | Sell | −15,888 | −$1.90M |
| 2026-08-04 | Patrick A Mayes | EVP & Chief Scientific Officer | MIXED | −2,187 | −$2.14M |
| 2026-07-27 | Michael James Morrissey | EVP, Head of Tech. Operations | A | +15,425 deriv. | — |
| 2026-07-27 | Lee Heeson | EVP, Head of Incyte Intl | A | +28,921 deriv. | — |
| 2026-07-20 | Richard A. Hoffman | EVP & General Counsel | A | +7,395 | — |
| 2026-07-20 | Pablo J Cagnoni | President, Global Head of R&D | A | +13,403 | — |
| 2026-07-20 | Mohamed Khairie Issa | EVP, Head of U.S. Commercial | MIXED | +6,764 | −$125.71K |
| 2026-07-20 | Ramitpal K Basi | EVP, Human Resources | A | +4,991 | — |
| 2026-07-20 | Patrick A Mayes | EVP & Chief Scientific Officer | A | +5,916 | — |
| 2026-07-20 | David H Gardner | EVP, Chief Strategy Officer | A | +7,395 | — |
| 2026-07-20 | William Meury | Chief Executive Officer | A | +26,807 | — |
| 2026-07-20 | Steven H Stein | CMO & Head of Late-Stage Dev. | MIXED | +7,921 | −$215.35K |
| 2026-07-20 | Thomas Tray | Principal Accounting Officer | A | +2,834 | — |
| 2026-07-16 | Pablo J Cagnoni | President, Global Head of R&D | F | −22,919 | −$2.63M |
| 2026-07-16 | Steven H Stein | CMO & Head of Late-Stage Dev. | MIXED | −53,155 | −$6.06M |
| 2026-07-16 | Mohamed Khairie Issa | EVP, Head of U.S. Commercial | F | −1,099 | −$126.48K |
| 2026-07-16 | Patrick A Mayes | EVP & Chief Scientific Officer | F | −1,949 | −$224.22K |
| 2026-07-16 | Thomas Tray | Principal Accounting Officer | F | −1,790 | −$205.87K |
| 2026-07-07 | Thomas Tray | Principal Accounting Officer | F | −477 | −$55.74K |
| 2026-07-07 | Patrick A Mayes | EVP & Chief Scientific Officer | F | −350 | −$40.90K |
| 2026-07-07 | Steven H Stein | CMO & Head of Late-Stage Dev. | F | −2,177 | −$254.40K |
| 2026-07-07 | William Meury | Chief Executive Officer | F | −4,779 | −$558.47K |
| 2026-07-02 | Paul J Clancy | Director | A | +252 | +$28.57K |
| 2026-07-02 | Edmund Harrigan | Director | A | +255 | +$28.91K |
| 2026-07-02 | Julian Baker | Director | A | +4,800 | — |
| 2026-06-10 | Jacqualyn A Fouse | Director | A | +1,642 | — |
| 2026-06-10 | Katherine A High | Director | A | +1,642 | — |
| 2026-06-10 | Otis W Brawley | Director | A | +1,642 | — |
| 2026-06-10 | Jean Jacques Bienaime | Director | A | +1,642 | — |
| 2026-06-10 | Paul J Clancy | Director | A | +1,642 | — |
| 2026-06-10 | Edmund Harrigan | Director | A | +1,642 | — |
| 2026-06-10 | Felix Baker | Director | A | +19,704 | — |
| 2026-06-08 | Thomas Tray | Principal Accounting Officer | MIXED | — | −$42.67K |
| 2026-06-03 | Pablo J Cagnoni | President, Global Head of R&D | F | −25,469 | −$2.43M |
| 2026-05-28 | Jean Jacques Bienaime | Director | MIXED | +1,941 | −$79 |
| 2026-05-28 | Thomas Tray | Principal Accounting Officer | Sell | −2,051 | −$199.66K |
INCY — Current Insider Holders
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| 667, L.P. | Director | 28,482,491 | $3.31B |
| Baker Bros. Advisors (GP) LLC | Director | 3,116,593 | $361.85M |
| Felix Baker | Director | 3,115,871 | $361.77M |
| Baker Brothers Life Sciences LP | Director | 3,098,808 | $359.79M |
| Herve Hoppenot | Special Advisor to the CEO | 352,703 | $40.95M |
| BAKER BROS. ADVISORS LP | Director | 314,600 | $36.53M |
| Julian Baker | Director | 314,600 | $36.53M |
| Pablo J Cagnoni | President, Global Head of R&D | 185,842 | $21.58M |
| William Meury | Chief Executive Officer | 183,129 | $21.26M |
| Christiana Stamoulis | EVP & Chief Financial Officer | 114,652 | $13.31M |
| Paula J Swain | EVP, Human Resources | 106,482 | $12.36M |
| Mohamed Khairie Issa | EVP, Head of U.S. Commercial | 71,797 | $8.34M |
| Patrick A Mayes | EVP & Chief Scientific Officer | 61,441 | $7.13M |
| Vijay K Iyengar | EVP, GMAPPS | 40,540 | $4.71M |
| Lee Heeson | EVP, Head of Incyte Intl | 37,578 | $4.36M |
| Barry P Flannelly | EVP & General Manager US | 35,149 | $4.08M |
| Michael James Morrissey | EVP, Head of Tech. Operations | 34,065 | $3.96M |
| Sheila A. Denton | EVP & General Counsel | 26,569 | $3.08M |
| Suketu Upadhyay | EVP & Chief Financial Officer | 26,343 | $3.06M |
| Paul J Clancy | Director | 25,838 | $3.00M |
| Jean Jacques Bienaime | Director | 24,424 | $2.84M |
| Edmund Harrigan | Director | 23,225 | $2.70M |
| Thomas Tray | Principal Accounting Officer | 21,699 | $2.52M |
| Steven H Stein | CMO & Head of Late-Stage Dev. | 21,118 | $2.45M |
| Jacqualyn A Fouse | Director | 20,968 | $2.43M |
INCY Insider Trading FAQ
Who are the insiders at INCY?
25 officers, directors and 10%+ beneficial owners currently report holdings in INCY via SEC Form 4.
Are INCY insiders buying or selling?
Across the 50 most recent Form 4 filings for INCY, 0 were open-market purchases (code P) and 6 were sales (code S). Sales frequently reflect scheduled 10b5-1 plans or tax withholding rather than a view on the stock.
How current is INCY insider data?
Form 4 must be filed within two business days of the transaction, so this is close to real time. The most recent INCY filing is dated 2026-10-19.
How to read Form 4 activity
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the INCY quote page; the site-wide leaderboard is on the insider transactions hub.
More on INCY
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.